SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone760-727-8399
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$143.44 million
Profitability
Miscellaneous
Employees361
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
SeaSpine (NASDAQ:SPNE) Frequently Asked Questions
What is SeaSpine's stock symbol?
SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."
How were SeaSpine's earnings last quarter?
SeaSpine Holdings Corp (NASDAQ:SPNE) announced its quarterly earnings data on Thursday, August, 1st. The medical equipment provider reported ($0.38) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.41) by $0.03. The medical equipment provider earned $39.31 million during the quarter, compared to analyst estimates of $38.95 million. SeaSpine had a negative net margin of 26.84% and a negative return on equity of 28.45%. View SeaSpine's Earnings History.
When is SeaSpine's next earnings date?
What guidance has SeaSpine issued on next quarter's earnings?
SeaSpine updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $155-157 million, compared to the consensus revenue estimate of $155.31 million.
What price target have analysts set for SPNE?
4 analysts have issued 1-year price targets for SeaSpine's stock. Their forecasts range from $19.00 to $22.00. On average, they expect SeaSpine's share price to reach $20.75 in the next twelve months. This suggests a possible upside of 93.2% from the stock's current price. View Analyst Price Targets for SeaSpine.
What is the consensus analysts' recommendation for SeaSpine?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SeaSpine.
What are Wall Street analysts saying about SeaSpine stock?
Here are some recent quotes from research analysts about SeaSpine stock:
- 1. According to Zacks Investment Research, "SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California. " (10/3/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $22 PT on SPNE. The strong execution that drove double-digit growth in 2H18 carried over into 2019 as SPNE posted 1Q revenue of $36MM (+9%), beating FactSet consensus by ~ $1MM, despite one less selling day, which we estimate likely created a 150bp headwind. SPNE is executing on its plan to add more exclusive distributors, increase proportion of revenue from recently launched products and progress against plan for staged launch of new products. SPNE raised the lower end of its 2019 sales guidance to $154-156MM (+7.5-9%), but we still consider guidance conservative and would not be surprised to see more beat and raises." (5/2/2019)
- 3. BTIG Research analysts commented, "We reiterate our Buy rating and $20 PT on SPNE following investor meetings in New York. High level takeaways from meetings noted an encouraging cadence of new product introductions in FY19 and beyond, a growing proportion of committed and exclusive distributors supporting SPNE’s portfolio, access to capital (without the need for additional funds in the next 3 years), achievable guidance, and an inexpensive valuation (absolute and relative). While 1Q is typically a seasonally softer quarter in spine, the outlook for FY19 is encouraging and if 2H18 is indicative of the momentum SPNE is seeing amongst its distributors and customers then a few more quarters of consistent execution should have shares re-rating at an improved multiple. We like SPNE’s set-up in FY19 as all the key pieces are in place for improved and continued momentum." (3/31/2019)
Has SeaSpine been receiving favorable news coverage?
News articles about SPNE stock have trended very negative this week, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. SeaSpine earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for SeaSpine.
Are investors shorting SeaSpine?
SeaSpine saw a increase in short interest in September. As of September 30th, there was short interest totalling 143,600 shares, an increase of 25.3% from the August 30th total of 114,600 shares. Based on an average daily volume of 42,000 shares, the days-to-cover ratio is currently 3.4 days. Approximately 1.0% of the shares of the company are short sold. View SeaSpine's Current Options Chain.
Who are some of SeaSpine's key competitors?
Some companies that are related to SeaSpine include Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), Cerus (CERS), SurModics (SRDX), Axonics Modulation Technologies (AXNX), AngioDynamics (ANGO), MiMedx Group (MDXG), Intersect ENT (XENT), Antares Pharma (ATRS), Orthopediatrics (KIDS), OraSure Technologies (OSUR), SI-Bone (SIBN), Utah Medical Products (UTMD), Alphatec (ATEC) and GenMark Diagnostics (GNMK).
What other stocks do shareholders of SeaSpine own?
Who are SeaSpine's key executives?
SeaSpine's management team includes the folowing people:
- Mr. Keith C. Valentine, Pres, CEO & Director (Age 51)
- Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 48)
- Mr. Patrick L. Keran, VP, Gen. Counsel & Corp. Sec. (Age 47)
- Carrie Mendivil, Head of Investor Relations
- Mr. John J. Winge, VP of Sales (Age 52)
Who are SeaSpine's major shareholders?
SeaSpine's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.05%). Company insiders that own SeaSpine stock include John B Henneman III, Keith Bradley, Michael Fekete, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for SeaSpine.
Which major investors are selling SeaSpine stock?
SPNE stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have sold SeaSpine company stock in the last year include Richard E Caruso and Stuart Essig. View Insider Buying and Selling for SeaSpine.
How do I buy shares of SeaSpine?
Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is SeaSpine's stock price today?
One share of SPNE stock can currently be purchased for approximately $10.74.
How big of a company is SeaSpine?
SeaSpine has a market capitalization of $204.70 million and generates $143.44 million in revenue each year. The medical equipment provider earns $-33,520,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. SeaSpine employs 361 workers across the globe.View Additional Information About SeaSpine.
What is SeaSpine's official website?
How can I contact SeaSpine?
SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]
MarketBeat Community Rating for SeaSpine (NASDAQ SPNE)
MarketBeat's community ratings are surveys of what our community members think about SeaSpine and other stocks. Vote "Outperform" if you believe SPNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
